NCT02912754 - Ruxolitinib Combined With Ibrutinib in Chronic Lymphocytic Leukemia Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2017

Primary Completion Date

December 31, 2018

Study Completion Date

August 31, 2019

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell

Interventions

DRUG

ruxolitinib

ruxolitinib will be added to ibrutinib or 3 out of 5 weeks per cycle

DRUG

ibrutinib

patients will be taking ibrutinib for at least 6 months and will continue to take it at the same dose and schedule while taking ruxolitinib

Trial Locations (2)

Sunnybrook Odette Cancer Center, Toronto

Sunnybrook Odette Cancer Center, Toronto